More than a year after trimming R&D unit, Ironwood adds a rare disease drug to the pipeline in hopeful step forward
Ironwood Pharmaceuticals has walked a less-than-easy path the past few years with a proxy-driven shakeup and multiple clinical failures rocking the company. Now under new leadership, Ironwood is snagging rights to a rare liver disease drug it hopes will serve as a springboard for its future plans.
Ironwood will pay $20 million upfront with the potential for an additional $475 million in downstream milestones for rights to CNP-104, an investigational candidate from Cour Pharmaceutical Development Company being tested in rare liver disease primary biliary cholangitis (PBC), the companies said Thursday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
